Tag: subjects

Posted on

Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects

Conditions:   Asthma (Part 1);   COPD (Part 2)
Interventions:   Drug: Dose 1, AZD8871 50 ?g (Part 1);   Drug: Dose 2, AZD8871 100 ?g (Part 1);   Drug: Dose 3, AZD8871 300 ?g (Part 1);   Drug: Dose 4, AZD8871 600 µg (Part 1);   Drug: Dose 5, AZD8871 1200 µg (Part 1);   Drug: Dose 6, AZD8871 1800 ?g (Part 1);   Drug: Placebo, AZD8871 placebo (Part 1);   Drug: Treatment A, AZD8871 dose A (Part 2);   Drug: Treatment B, AZD8871 dose B (Part 2);   Drug: Treatment C, Indacaterol 150 ?g (Part 2);   Drug: Treatment D, Tiotropium 18 ?g (Part 2)
Sponsor:   AstraZeneca
Not yet recruiting – verified October 2015

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Posted on

Demographic Characteristics of Asthma Subjects Associated With Stepping Down … – AJMC.com Managed Markets Network

Demographic Characteristics of Asthma Subjects Associated With Stepping Down …
AJMC.com Managed Markets Network
Methods: Subjects were included if they: 1) had ?2 FSC prescription claims prior to the index (step-down) date, 2) had ?1 asthma claim, 3) were aged 12 to 64 years, and 4) were continuously eligible for 12 months pre- and post index. Subjects were …

View full post on asthma – Google News

Posted on

Relative Bioavailability Study of Two Montelukast Sodium (GW483100) 5 Milligrams (mg) Chewable Tablets and One Reference Montelukast Sodium 5 mg Chewable Tablet in Healthy Adult Subjects

Condition:   Respiratory Disorders
Interventions:   Drug: Reference Montelukast;   Drug: Test 1 Montelukast;   Drug: Test 2 Montelukast
Sponsor:   GlaxoSmithKline
Not yet recruiting – verified December 2014

View full post on ClinicalTrials.gov: asthma | received in the last 14 days